tiprankstipranks
Trending News
More News >
Apellis Pharmaceuticals (APLS)
NASDAQ:APLS
US Market

Apellis Pharmaceuticals (APLS) Income Statement

Compare
999 Followers

Apellis Pharmaceuticals Income Statement

Last quarter (Q4 2025), Apellis Pharmaceuticals's total revenue was $199.91M, a decrease of -5.94% from the same quarter last year. In Q4, Apellis Pharmaceuticals's net income was $-58.95M. See Apellis Pharmaceuticals’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 25Dec 24Dec 23Dec 22Dec 21
Total Revenue
$ 1.00B$ 781.37M$ 396.59M$ 75.42M$ 66.56M
Gross Profit
$ 901.55M$ 663.64M$ 338.08M$ 69.79M$ 61.36M
Operating Expenses
$ 846.12M$ 828.62M$ 855.20M$ 664.40M$ 597.64M
Depreciation and Amortization
$ 1.56M$ 1.80M$ 1.70M$ 1.49M$ 1.49M
EBITDA
$ 70.00M$ -154.53M$ -495.21M$ -617.39M$ -731.27M
Operating Income
$ 55.43M$ -164.98M$ -517.12M$ -594.61M$ -536.28M
Other Income/Expenses
$ -31.32M$ -31.74M$ -9.38M$ -56.89M$ -209.72M
Pretax Income
$ 24.11M$ -196.72M$ -526.50M$ -651.50M$ -746.00M
Net Income
$ 22.39M$ -197.88M$ -528.63M$ -652.17M$ -746.35M
Per Share Metrics
Basic EPS
$ 0.18$ -1.60$ -4.45$ -6.15$ -8.84
Diluted EPS
$ 0.18$ -1.60$ -4.45$ -6.15$ -8.84
Weighted Average Shares Outstanding
126.02M 123.91M 118.68M 106.11M 84.42M
Weighted Average Shares Outstanding (Diluted)
126.02M 123.91M 118.68M 106.11M 84.42M
Currency in USD

Apellis Pharmaceuticals Earnings and Revenue History